Bio-Techne Corporation (TECH) Earnings Call Transcript & Summary
May 6, 2026
What were the key takeaways from Bio-Techne Corporation's May 6, 2026 earnings call?
In the third quarter of fiscal year 2026, Bio-Techne Corporation reported total revenue of $311.4 million, reflecting a 2% decline both organically and on a reported basis. Adjusted EPS was $0.53, down $0.03 year-over-year, while GAAP EPS increased to $0.32 from $0.14. Management indicated that organic growth was flat for the fourth quarter, with expectations for low single-digit growth in the underlying portfolio, signaling cautious optimism for fiscal 2027 driven by improving conditions in the U.S. academic market and a potential recovery in emerging biotech spending.
What topics did Bio-Techne Corporation cover?
- Organic Revenue Decline: Bio-Techne experienced a 2% organic revenue decline in Q3, attributed to 'continued softness in emerging biotech spending.' Management noted that underlying organic revenue growth was 2% when excluding specific headwinds.
- Strong Performance from Large Pharma: The large pharmaceutical customer segment delivered its sixth consecutive quarter of double-digit growth, driven by sustained investment in discovery and translational research. Management stated, 'Revenue from our large pharma customers grew low double digits.'
- Spatial Biology Portfolio Growth: The Spatial Biology portfolio achieved mid-teens growth, with the COMET platform showing over 65% growth. Management highlighted, 'We exited the quarter with another record backlog for the COMET platform.'
- Profitability Focus: Bio-Techne maintained a strong focus on profitability, with an adjusted operating margin of 34.2%, representing a 310 basis point improvement sequentially. Management emphasized their commitment to 'delivering sector-leading profitability while continuing to invest in growth factors.'
- Emerging Biotech Spending Concerns: Management noted a significant decline in emerging biotech revenues, which fell high single digits. They acknowledged that 'the typical lag in spending following funding constraints' has impacted performance.
What were Bio-Techne Corporation's May 6, 2026 results?
- Total Revenue: $311.4 million (-2% YoY)
- Adjusted EPS: $0.53 (down $0.03 YoY)
- GAAP EPS: $0.32 (up from $0.14 YoY)
- Adjusted Operating Margin: 34.2% (up 310 basis points sequentially)
- Organic Revenue Growth: 2% (excluding specific headwinds)
- GMP Protein Revenue Growth: nearly 50% (year-over-year when excluding 2 fast track cell therapy customers)
Bio-Techne's mixed performance in Q3 reflects ongoing challenges in emerging biotech while highlighting strengths in large pharma and spatial biology. The cautious guidance for Q4 suggests a wait-and-see approach as management anticipates a recovery in fiscal 2027. Investors should monitor the biotech funding landscape and the company's ability to capitalize on improving academic conditions as key catalysts for future growth.
Earnings Call Speaker Segments
Hello, everyone, and thanks for being with us today. Joining me on this morning's call are Bio-Techne's President and Chief Executive Officer, Kim Kelderman, along with our Chief Financial Officer, Jim Hippel. Ahead of getting started, I'd like to take a moment to go over the safe harbor statement. A portion of what we say on this conference call could be classified as forward-looking statements, which include beliefs and expectations regarding the company's future results. In the company's 10-K for fiscal 2025, certain factors are identified that might lead to the company's actual results differing materially from those projected in the forward-looking statements given during this call. The company does not commit to updating any forward-looking statements as a result of new information, future events, or developments. The 10-K, along with the company's other SEC filings, can be found on the company's website in its Investor Relations section. Non-GAAP financial measures might be used during the call to supply information pertinent to ongoing business performance. Tables that reconcile these measures to the most comparable GAAP measures appear in the press release the company issued earlier this morning, which is available in the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com. On a separate note, over the next few weeks, we'll be taking part in the Bank of America and Jefferies Healthcare Conferences, and we're eager to connect with many of you at those upcoming events. I'll now hand the call over to Kim.
Dave, thanks, and good morning everyone. We're glad to have all of you join us for Bio-Techne's fiscal 2026 third-quarter earnings call. Throughout a dynamic and uneven end market, the Bio-Techne team continued to execute with discipline. Our quarterly results were buoyed by ongoing strength among large pharmaceutical customers and by trends in the U.S. academic end market that were stable to improving. Those gains were partly offset by persistent softness in emerging biotech spending, which led to a 2% drop in organic revenue for the quarter. Importantly, encouraging indicators are starting to appear that suggest continued improvement in U.S. academia as well as an eventual rebound in emerging biotech, and that leaves us positioned well for a stronger fiscal 2027. During the quarter, we faced a 400 basis point drag, which stemmed from how orders lined up for two cell therapy clients holding FDA Fast Track Designation, plus the scheduling of a sizable commercial supply order from an OEM — all of which we flagged on our last earnings call. Strip those items out, and organic revenue rose 2% at its core. Several things stood out in our third quarter: growth in the mid-teens came from our Spatial Biology portfolio, and we closed the period with yet another record backlog for COMET. Setting aside those two fast track cell therapy accounts, our GMP protein portfolio climbed almost 50% compared with a year earlier. Meanwhile, mid-single-digit expansion came within our Proteomic Analysis franchise, propelled by beneficial instrument placements and usage patterns. For the fourth quarter in a row, our end market in China posted positive organic growth. Meanwhile, large pharma—our biggest end market—notched its sixth straight quarter of double-digit growth. Profitability also stayed a top priority for us. In the third quarter, adjusted operating margin came in at 34.2%, which is a 310 basis point improvement sequentially from fiscal Q2. Later on this call, Jim will walk through more specifics on how we performed financially. At this point I'll move to our end markets, starting with biopharma but leaving out cell therapy. There, a gap persists between how large pharma is doing and how emerging biotech is doing. Sales to our large pharma customers rose by a low double-digit rate, fueled by ongoing spending on discovery, translational research and manufacturing. For emerging biotech, though, sales were down by a high single-digit rate, which mirrors the usual delay in spending that comes after the funding squeeze seen during the first half of calendar 2025. Since then, biotech funding has bounced back substantially, with estimated gains exceeding 90% in our fiscal Q2 and 50% in fiscal Q3. Because customer spending typically trails funding by 2 to 3 quarters, we see this as a favorable backdrop for fiscal 2027. On the academia side, the team posted low single-digit expansion, as the U.S. academic market resumed growing in the third quarter. Better new grant activity from the NIH, along with a 1% bump to that agency's budget, has cut down on how uncertain funding looks and puts this end market in a spot where it can keep stabilizing. Looking at regions, the Americas were down by a low single-digit rate, but Europe managed mid-single-digit expansion. Both of our top two fast track cell therapy accounts show up inside the North America figures. As for Asia, growth landed in the low single digits there, and China has now kept up its momentum for a fourth quarter running. In China, biopharma and CRO customers centered on antibody drug conjugates, cell therapy and autoimmune disorders keep pushing demand higher. These areas happen to be exactly where our analytical platforms, instruments, and reagents are a particularly strong match. Back in April, Bio-Techne shared news of a strategic brand alignment meant to simplify our portfolio, taking it from 10 brands to just 3. With that alignment, customers can more easily work with Bio-Techne across the continuum from research through clinical. The 3 brands we now have include R&D Systems, which brings together our entire range of research use only and GMP reagents together with proteomic analysis instruments that previously carried the ProteinSimple brand. We've grouped RNAscope in situ hybridization kits and reagents together with the COMET Multiomic Spatial platform under Bio-Techne Spatial Biology, while clinical controls and precision diagnostic solutions now sit within Bio-Techne Diagnostics. With this setup, our offerings and technologies line up more closely with how customers advance from discovery, through translational research, and on into clinical and diagnostic use. It also gives our solutions greater visibility on digital and AI-driven platforms, so customers can more easily find and put the right tools to work in their workflows. On the artificial intelligence front, we continue to watch AI play a growing role both in how we operate internally and in how our customers go after drug discovery. Within our organization, artificial intelligence is applied to create new proteins that can be patented, offering better characteristics such as greater resistance to heat, stronger biological activity, and higher solubility compared with versions found in nature. It's well understood that the effectiveness of AI systems depends entirely on the quality of information used to train them. Our models are trained on fifty years of exclusive data, which creates a substantial barrier for competitors. In parallel, we're deploying AI throughout the company to enhance efficiency and deepen interactions with customers. When it comes to customers, the use of AI is accelerating the initial stages of drug development, particularly the identification of targets, which ought to expand the pool of promising programs and increase the likelihood of success. The effectiveness of these models depends heavily on producing biological data of high quality, and Bio-Techne occupies a very powerful position in that area. One example: Providence Health and Microsoft recently published a collaboration on the GigaTIME AI framework, which drew on data sets created through COMET, Bio-Techne's Spatial Biology platform, to turn standard H&E pathology images into virtual 3-dimensional tissue representations. We see growing appetite for content-rich biological data sets as a lasting tailwind behind our spatial biology offerings as well as our proteomic analysis platforms. In addition, AI acts as a downstream demand driver for RUO reagent and assay portfolios. Down the road, any insight generated with AI has to be confirmed biologically. That requirement will fuel demand for antibodies with a high degree of specificity, for functional assays, and for intricate recombinant proteins used in mechanism of action work, biomarker validation, and preclinical processes. Those uses map squarely onto the areas of our portfolio that stand apart from competitors and carry the greatest value. Let's turn now to our segments, beginning with Protein Sciences, where organic revenue declined 4% during the quarter. If you factor in the timing of orders from the cell therapy and OEM commercial supply customers we mentioned before, the underlying growth rate works out to 2%. Our portfolio of reagents, instruments and analytical technologies — which sets us apart from competitors — continues to serve as the foundation for developing and manufacturing advanced therapeutics, cell therapies among them. A reminder: FDA Fast Track Designation went to 2 of our biggest cell therapy customers, and that sped up their clinical time lines while lowering near-term demand for GMP reagents, since those customers had already obtained the materials needed to finish their clinical programs. If you set aside what those 2 customers contributed, GMP protein revenue was up almost 50% versus the prior year. Such a robust result from emerging cell therapy customers highlights how much more these programs depend on GMP-grade cytokines and growth factors as they move from early development through clinical trials and on into manufacturing scale-up and commercialization. Still on the cell therapy topic, a quick Wilson Wolf update. Our current stake in Wilson Wolf stands at 20%, and we expect to be on track to buy the rest of this maker of the market-leading line of single-use bioreactors known as the G-Rex by the close of calendar 2027, or possibly sooner if certain milestones are met. Even with biotech funding conditions proving difficult, Wilson Wolf posted low double-digit growth measured on a trailing 12-month basis, all while keeping EBITDA margins above 70%. Now to our proteomic analysis instruments.
On this call, expansion came primarily from greater operating uptake of our Ella benchtop immunoassay system. With Ella, conventional immunoassays get automated into a cartridge-based process, which yields fast protein quantification that is highly reproducible and requires very little hands-on effort. Those characteristics are fueling robust uptake within neurodegeneration research, and you can see that in a 50% CAGR over 3 years for our neurology assay portfolio. Although this is still an emerging piece of the business, the recent introduction of ultrasensitive capabilities bolsters Ella's standing as a top platform for analyzing blood-based neurological biomarkers. In the quarter, we additionally secured CE-IVD marking for Ella, which allows hospitals, clinical laboratories or other European organizations to employ Ella as a validated platform for clinical uses, in-house test development, clinical trials or other translational work. We likewise experienced ongoing momentum in our biologic characterization portfolio, headed by our Maurice platform. Maurice is becoming more deeply integrated into biopharma manufacturing workflows as a quality control and characterization instrument. It supports quicker, more uniform evaluation of critical protein attributes, such as size, charge and purity. That generated double-digit growth for both Maurice instruments and consumables. To close out Protein Sciences, our core reagent and assay portfolio, spanning over 6,000 proteins and 400,000 antibody types, fell mid-single digits during the quarter. If you set aside the effect of order timing tied to the previously mentioned OEM commercial supply customer, organic growth was down low single digits. Gains from large pharma customers were outweighed by ongoing weakness in U.S. academic demand and the residual impact of last year's difficult biotech funding environment. As funding conditions keep normalizing in academia and recent biotech funding improvements convert into customer spending, we think this core portfolio is positioned well to get back to growth, underpinned by its differentiated performance in bioactivity, lot-to-lot consistency and reproducibility. Those are all attributes that grow more and more essential as customer programs move toward translational and regulated applications. Turning to Diagnostics and Spatial Biology, the segment posted 3% organic revenue growth for the quarter. Before going deeper into the performance, I want to congratulate Steve Crouse on being promoted to President of the segment. We're eager to see Steve build on his earlier success leading our Analytical Solutions business across the past 5 years. Let's start with our recently rebranded Bio-Techne Spatial Biology portfolio, where we keep reinforcing our leadership in situ hybridization and mid-plex multiomic applications spanning translational and clinical research. Robust order momentum in recent quarters converted into over 65% growth for our COMET Multiomic Spatial Platform. In the quarter, we placed the first COMET system in China, a significant milestone as demand keeps building in the region. We closed the quarter with yet another record backlog for the COMET, which sets the platform up for continued growth. Results in our RNAscope portfolio of in situ hybridization kits and reagents strengthened to high single-digit growth. That growth came from additional customer adoption in EMEA and Asia, along with rising use in clinical diagnostic applications in the U.S. To wrap up, our Diagnostics segment, which was just renamed Bio-Techne Diagnostics, saw a low single-digit decrease, since the timing of orders from a few big customers had a short-term effect on what we delivered. Because so much of this business comes from a handful of major accounts, results can swing around from one quarter to the next. So I'd like to note that measured over the trailing 12-month period, Bio-Techne Diagnostics still grew in the low single digits. Taking a step back, the Bio-Techne team kept executing well amid a mixed set of end markets. Large pharma customers are still showing robust demand. Our U.S. academic segment has steadied, and momentum keeps building for us in China along with the wider APAC region. Although spending among emerging biotech firms has not yet caught up fully with better funding conditions, the level of engagement and activity with those customers keeps moving in a positive direction. We stay very disciplined about running this business, turning in sector-leading profitability even as we keep putting money into the growth drivers that will define what Bio-Techne becomes. As funding visibility improves for our customers, and with strong standing in our core reagents, cell therapy, proteomic analysis and spatial biology solutions, we think Bio-Techne is positioned well to outperform in the coming years. On that note, I'll hand things over to Jim. Jim?
Thank you, Kim. I'll start by providing some further specifics regarding how we did financially in Q3, and then I'll share my perspective on what lies ahead. For the quarter, adjusted EPS landed at $0.53, which is $0.03 lower than the same period a year ago, with currency movements contributing a positive $0.02. On a GAAP basis, EPS reached $0.32, compared with $0.14 during last year's corresponding quarter. Q3 total revenue amounted to $311.4 million, a decline of 2% whether measured organically or as reported. Currency exchange provided a 2% benefit, whereas the earlier sale of Exosome Diagnostics produced a 2% drag. A timing effect involving our 2 biggest cell therapy customers, who had obtained FDA Fast Track Designation, subtracted 3%, and a sizable OEM commercial supply order that normally lands in Q3 but came in Q2 this year took away another 1% of revenue. Once those previously disclosed factors are excluded, organic growth for the quarter was positive 2%. Looking geographically, North America fell by a low single-digit rate, since gains from large pharma and academic growth were countered by cell therapy order timing and a biotech end market that has not yet turned upward despite improving funding conditions. European revenue climbed at a mid-single-digit pace, which included low single-digit expansion in biopharma plus mid-single-digit growth among academic customers there. We take encouragement from a fourth straight quarter of growth in China, where revenue rose at a low single-digit rate. APAC outside of China likewise grew low single digits against a very tough comparison, as that region keeps displaying evidence of lasting recovery. Turning to end markets, biopharma as a whole slipped by a low single-digit percentage. Yet if you set aside our biggest cell therapy customers, biopharma achieved low single-digit growth, powered by robust pharma demand while being partly held back by weakness among emerging biotechs. Academia rose low single digits, as stabilizing patterns transitioned into low single-digit growth within the U.S., while Europe posted mid-single-digit growth. Further down the income statement, adjusted gross margin reached 70.4%, lower than last year's 71.6% yet 190 basis points better than the previous quarter. The drop versus a year ago stemmed from an unfavorable product mix. Adjusted SG&A represented 28.7% of revenue, a 30 basis point improvement from 29% a year earlier. R&D expense was 7.5% versus 7.8% in the comparable prior-year period. This operating leverage shows the gains from structural streamlining and careful cost control, partly offset by focused spending on strategic growth efforts. Adjusted operating margin came to 34.2%, a year-over-year decrease of 70 basis points. That reduction resulted from unfavorable mix and volume deleverage, partly countered by the Exosome Diagnostics divestiture. Beneath operating income, net interest expense totaled $1.3 million, which is $0.4 million higher than a year ago because interest rate hedges expired. Bank debt finished the quarter at $200 million, a sequential reduction of $60 million. Other adjusted net operating income was $1.3 million, $1.8 million below the previous year, largely reflecting nonrecurring foreign exchange gains from a year ago tied to overseas cash pooling arrangements. Our adjusted effective tax rate came in at 22.3%, 80 basis points above the prior year, owing to geographic mix. Now moving on to how we're handling cash and putting capital to work. Operating cash flow came in at $86.7 million, while net capital expenditures totaled $9.1 million. In Q3 as well, we gave back $12.5 million to shareholders through dividends, and we closed out the quarter with 157.4 million average diluted shares outstanding, which is a 1% decline versus a year ago. Our balance sheet is still in solid shape, with $209.8 million in cash and a total leverage ratio that sits comfortably under 1x EBITDA. When it comes to allocating capital, M&A continues to rank as our highest priority. Let's now go through how each segment performed, starting with Protein Sciences. Sales as reported for Q3 reached $226.2 million, which is a 1% drop compared with the prior-year period. Organic revenue fell 4%, though foreign exchange contributed a 3% benefit. If you set aside the timing effects from cell therapy and OEM commercial supply tied to our biggest customers, organic growth came in at plus 2%. The Proteomic Analysis instrument franchise drove that growth, helped by ongoing momentum among large pharma along with double-digit gains from our academic end market. As Kim noted, our core portfolio of research reagents and assays was down mid-single digits, which mirrors the tough biotech backdrop and the ongoing drag from the U.S. government shutdown on grant activity and fund outlays during the quarter. Once you exclude the timing effect of one large commercial supply customer, that core portfolio decline was only in the low single digits. Operating margin for Protein Sciences landed at 44.2%, a 140 basis point decrease from a year ago, mainly because of unfavorable product mix and volume deleverage, with ongoing profitability initiatives providing a partial offset. Over in our Diagnostics and Spatial Biology segment, Q3 sales totaled $85.6 million, a 4% decline year-over-year. The Exosome Diagnostics divestiture dragged reported growth down by 8%, whereas foreign exchange gave a 1% favorable lift, leaving the segment with 3% organic growth. Bio-Techne Diagnostics slipped low single digits as order timing from certain large customers weighed on growth. Spatial Biology was up mid-teens, and that includes over 65% growth from our COMET platform, while our RNAscope portfolio rose high single digits. Segment operating margin rose to 12.1%, compared with 9.4% last year, lifted by the Exosome Diagnostics divestiture and productivity initiatives, partly offset by unfavorable mix among our OEM customers. We anticipate further margin expansion in line with the scaling of our COMET Spatial Biology platform. As we prepare to wrap up the rest of our fiscal year 2026, our attention stays on the things within our control; that means operational and commercial execution, productivity and capital discipline, and delivering sector-leading profitability while continuing to invest across our growth platforms. Conditions in our pharma end market are still robust. The stabilization and early signs of gradual improvement in the U.S. academic market are a positive signal. Biotech funding levels have been extremely strong over the past 2 quarters, and our commercial teams say they're seeing more engagement and a larger opportunity funnel from these customers. That said, because of the timing lag between funding and spending among biotech customers, which is usually 2 to 3 quarters, we see this end market as the largest swing factor for growth to pick up from here. Even though improvement in the biotech end market might begin to show up as soon as our June quarter, what we consider our base case is that a significant rise in growth won't arrive until the first half of fiscal year 2027. As Kim said before, we're also still encouraged by how our biggest cell therapy customers are progressing after receiving FDA Fast Track designation. Those designations do temporarily lower near-term demand for GMP reagents while these customers move through their Phase III trials, but they considerably speed up possible commercial time lines; this customer-specific headwind eases in the fourth quarter, affecting growth by roughly 150 basis points year-over-year, and it will be entirely out of our comparisons once we get into fiscal 2027. With these market and customer-specific dynamics factored in, we expect organic growth in the fourth quarter to come in at approximately flat. If you set aside the effect of the cell therapy headwinds, we anticipate low single-digit underlying growth across the rest of the portfolio; this outlook assumes end market conditions are broadly in line with what we saw in Q3. And any additional stabilization or improvement in emerging biotech spending might turn out to be additive. Importantly, this near-term outlook leaves us well positioned for an acceleration in fiscal 2027 as biotech funding should translate more fully into customer spending, academic conditions keep normalizing, company-specific timing headwinds roll off, and we lap easier year-over-year comparisons. From a margin standpoint, we remain focused on balancing growth investments against operational efficiency and plan to finish the last quarter of the year with roughly 100 basis points of margin expansion compared with the prior year; that wraps up my prepared remarks. I'll hand the call back to the operator to open the line for questions.
I'd like to build on what was said about emerging biotech, which declined by a mid-single-digit rate during the fiscal second quarter, and you noted a high-single-digit drop for this quarter, while recognizing that better funding might only show up later in the year. Given that downward shift, I'm interested in what you observed in terms of trends within the quarter, and whether any pickup appeared from January through March and continuing now into April.
Matt, thanks for asking. The biotech end market genuinely caught us off guard, so I'm glad you focused on it. Naturally, we had extremely clear sight into the funding situation. As you'll recall, funding looked pretty bleak across the first half of 2025, calendar 2025. It recovered somewhat, reaching low single digits during the third quarter, before experiencing a genuine jump of 90% growth in Q4. Then we moved into the new calendar year with another solid quarter for funding. Beneath all that, our prior 2 quarters came in at negative mid-single digits 2 times running, which pointed toward a degree of stabilization. Add to that the funding being up, interest rates stabilizing as we knew, biotech M&A deals rising along with licensing deals equally so, plus we had a bit of sight into positive COMET bookings. So we projected a modest uptick for the biotech end market, perhaps to negative low single digits. Yet as you said, it instead fell to negative high single digits. That essentially accounts for our entire quarter, and it aligns quite neatly with precisely the shortfall in our biotech end market. There, naturally, we dug deeper, and it becomes apparent that funding climbed considerably among late-stage biotech companies, yet for early-stage biotech, where a bigger share of our core reagents has a direct read, that early-stage funding had in fact fallen once you break it out. That's precisely where the surprise hit us. On the trend within the quarter, our sales force tells us there's greater interaction and dialogue regarding potential orders and investments; however, at this point, given 2 negative mid-single-digit quarters shifting to high negative singles, we cannot assume any clear stabilization or improvement exists. So at present, we're holding our forecast at flattish, since we lack clear indicators of an improvement.
All right. All right. That's reasonable. Then you mentioned what we should expect for Q2 on the calendar, and as I consider how a few of your bigger competitors have described both that period and how the remainder of the year plays out, with OEM timing and cell therapy headwinds no longer dragging on your comparisons, plus a bit of strengthening in A&G — I'd just like to know whether you see something in the mid-single-digit range as we close out the year, again roughly in line with the gains others are pointing to, if that makes sense, or whether there's a different range we ought to consider? That's everything from me.
Jim here. Appreciate the question. Let me confirm I've got it right. You're referring to the close of calendar '26.
Yeah. That's correct. Right. Only because of the way competitors have described the calendar second quarter in relation to the rest of the year.
Yeah, absolutely. Yeah, what I'd say is, once again, we're not going to provide anything like even loose guidance regarding '27 until the following quarter. That said, as I noted during my prepared remarks, the coming fiscal year has us quite optimistic. A number of those headwinds specific to the company will at last be in the rearview. Plus, we're observing — we have observed clear stabilization across the North American academic market. And pharma, naturally, continues to be robust. So for us, it truly boils down to biotech; and I'll admit, I think we probably were somewhat — after witnessing 2 quarters of stabilization in biotech, we figured maybe the worst had passed. Looking back, though, we might have been somewhat — put the cart somewhat ahead of the horse there, in that the truth is, say, that lag of 2 to 3 quarters actually hasn't materialized yet, since there have only been 2 quarters — 2 recent quarters in which funding has been strong; yet it does — assuming history offers any signal, it does promise a great deal for the back half of calendar '26 when it comes to the biotech market. And naturally, that represents our first fiscal quarter of '27. It's also heartening to hear from peers who've already reported that they too anticipate a pickup in momentum during the latter half of the year, and that thesis is one we generally share.
So, Jim, starting with you — we're only 1 quarter out from fiscal '27. Given how long we've all been operating in these markets, you're fully aware of the difficulties involved. Is mid-single-digit growth still achievable? Can Bio-Techne still deliver mid-single-digit growth in fiscal '27? I believe that's a crucial thing to ask, considering where we've landed so far. And regarding the biotech side, I get it, but I'm just trying to figure out whether, with the end market difficulties, anything caught you off guard later on in the quarter? Or does this come down more to how you're putting together the overall forecast, since I don't believe investors anticipated a surprise at this stage, especially after the GMP Fast Track designations already caught people off guard 2 quarters back.
Yes. Puneet, I appreciate the question. This is Jim. So yes, on the subject of fiscal year '27, I mean, through the lens we currently have, yes, we'd be let down if we didn't achieve at minimum mid-single-digit growth, since every indicator suggests the market is steadily normalizing. And let me remind everybody that if you set aside those company-specific items, which come down to 3 customers, we'd have posted low single-digit growth even in the current environment, with a challenging biotech end market. So yes, I believe we'd be let down. And regarding the indicators we're watching, we mentioned that in academic, we genuinely observed a pickup in growth across our proteomic analysis instrument portfolio and our spatial portfolio as well. And you've heard this from us previously, Puneet — those 2 in particular, those 2 growth vectors for us, serve as something like indicators for us when the markets begin recovering; that's typically where money goes first. And that's precisely where we saw quite encouraging growth in U.S. academic this quarter, which gives us greater confidence that our customer base is gaining more confidence in their funding there. And that's likewise what we're watching when it comes to our biotech customers as an indicator of that inflection point; and once more, it's too soon to declare it right now, which is why we're being, I think, fairly prudent with our Q4 forecast by kind of keeping it steady in terms of overall base improvement; but it was encouraging to hear from our businesses and our commercial leads that interest in — especially our proteomic analysis and our spatial biology offerings has risen lately among our biotech customers, and the funnels there are beginning to grow once more. So we'll see whether that turns into additional orders in Q4 for greater revenue in early fiscal year '27; those are what we'll be watching for from our biotech end market.
Understood. And beyond that — that's useful; and beyond that, regarding the RUO reagent side, I believe you mentioned that this business is weak, in part because emerging biotech is the cause. Yet we've observed 2 readouts from 2 competitors up to this point. One of them, as an OpCo beneath a bigger entity, is seeing its business recover there. Another one that's robust in flow cytometry is likewise displaying growth signals. So how should we — what makes you confident this isn't any share loss at R&D Systems and Novus Biologicals?
Yes, Puneet, thank you. Yes, quite a good question. The — actually, a few dynamics at play here. That single order we discussed that was booked in Q2 rather than Q3, the 100 basis point swap we've referenced before and during this earnings call, is in fact within that figure; it resides in that core reagents segment; and when you examine our comparables with double-digit growth the prior year, it was nearly 20% last year. And versus some of those other companies you're mentioning that have negative numbers to compare against, we've run our calculations and done our diligence and, naturally, our market research; and we're fairly confident that we're in fact still quite well positioned, and that's the case for that core business.
Absolutely. Let me also mention this, Puneet — when folks consider our core reagents, their minds usually go to the proteins and antibodies lineup, and that's fair. However, we should note that small molecules are part of it too, along with assays — core ELISA assays and similar items. Still, when it comes specifically to that proteins and antibodies lineup, once you remove that single very large OEM order from one customer that hit that segment of our portfolio, our proteins and antibodies together, on a combined basis, were up in the low single digits for this quarter.
Kim, perhaps a question regarding the China segment, which keeps displaying a bit of expansion over there. Could you describe what you're observing, and then how visible the outlook is moving forward? Do you feel like you're sitting in a fairly strong position as we move toward '27? We'd appreciate additional specifics on the broader environment and what's expected there.
Patrick, I appreciate you asking. Indeed, we're very thrilled that China has delivered positive growth for a fourth time. And clearly, Jim and I traveled to China earlier this quarter, where we met with government officials, looking into ways we can keep aiding science and medicine in that nation. We engaged with customers across academia together with the emerging businesses pursuing novel therapeutics, such as CROs and CDMOs. And plenty is happening. Momentum in that market is plainly visible, particularly concerning advanced therapeutics. So from our standpoint, being back in growth mode doesn't come as a shock; we predicted that correctly 12 months ago. And nothing suggests that this will lose steam. My expectation is that momentum will persist and that specific end market will keep getting stronger, especially following our trip. We operate directly in that market, and our team maintains strong connections with customers across both sides, spanning biotech together with pharma and also academia. And yes, everything about it is encouraging.
All right, that's useful. And perhaps just one additional item regarding the biotech segment. Once again, that's an unexpected decline. I suppose when it comes to your discussions with customers, what are you picking up? I mean, funding has appeared pretty strong for more than 6 months now. Usually, that tends to trigger an upward inflection for your business. I'm just wondering, I suppose, about the visibility, the customer discussions, and how you feel regarding that market as you move toward '27. It seems like it ought to have been a solid tailwind, particularly heading into the coming quarter and '27. Clearly, it has trailed off somewhat. Just attempting to determine how that might shape up as we progress forward over the coming 6, 9 months.
Patrick, I believe Jim already addressed that, correct? So the decline caught us fairly off guard — following additional analysis and when you examine funding levels for early-stage biotech and later-stage biotech, we get it. Yet you're correct, those funding levels were quite encouraging. And as I stated, interest rates, M&A deals, all of those were signaling the right direction. I already noted that the discussions are improving. The level of interest from the biotech market is getting better. And during the prior quarter, with 2x negative mid-single digits, we believed stabilization and improvement had arrived. But given the decline, we're returning to, okay, stabilization is typically our next milestone because we need to witness the ship turn the corner. And so, we are being somewhat cautious; and I believe that's the appropriate approach. Yet you're correct, every indicator, including the dialogue with customers, is positive.
Also, let me tack on something brief here. I suppose this ties back to what I said earlier about putting the cart ahead of the horse — we're essentially attempting to pinpoint something very precise, namely which specific quarter marks that turning point. We've noted that after reviewing how things have played out across many decades, examining the various ups and downs in biotech financing, the span runs from as little as 1 quarter all the way to 4 quarters, though the typical or average figure lands somewhere in the 2-to-3 range. The truth is, we've only had 2 quarters so far of healthy funding. That puts us essentially at that midpoint right now. We'll find out if any of that acceleration shows up in Q4. As things stand, our base case assumes it won't, though by the same token things don't have to deteriorate further from this point. Still, this does, once more, give us reason for optimism about the latter portion of this calendar year, which corresponds to the first half of our fiscal year, since by then you begin reaching what you might call the far end of the bell curve — the point where that benefit typically starts showing up.
I'll continue along the same thread of questioning. Jim, could you give us your outlook for the fourth quarter across the various end markets? What's your take on academic — U.S. academic — biotech, and so on? Then, as well, if you drill into the funding analysis, what kinds of competitive dynamics, if any, did you find? Part 3 of that would be: which areas of the portfolio do you expect to recover first — among the EVP customers?
Okay, I'll handle the first one. Appreciate the question. I'll handle the first one plus the third one, and I'll have Kim weigh in on the second point. Quite straightforward, without walking through each end market individually — the plain answer is that our base case assumes essentially the same performance level across every end market in Q4 as what we observed in Q2. Pharma is already quite strong. Academic is heading the right way, even if gradually. Consequently, we don't anticipate a significant shift, yet still ongoing improvement. Then for biotech, we're assuming the same sort of performance in Q4 as what we observed in Q3. As I mentioned during my opening comments, that would be the — that will be — if any upside potential exists, that's where we believe we could find it, namely biotech. But at present, that isn't our base case. So that's essentially how we're looking at the end markets. Regarding — I was going to handle the third bullet, I'm trying to recall what it was now. It concerned — remind me...
Where within the portfolio do you expect biotech's rebound to first show up?
Yeah, thanks. So to repeat what I said when addressing a question earlier, we examine how we're performing — in particular our proteomic analysis business and our spatial business, those 2 growth vectors; cell therapy sort of marches to its own beat, though that one is already performing quite strongly. For us, those 2 growth vectors typically serve as an early signal about a market turn once we observe them beginning to inflect. And much like those 2 segments of our business delivered double-digit growth across our U.S. academic markets this most recent quarter, that's the same thing we're watching for as the inflection point in biotech; and as I said, I don't want to get ahead of us, but it was encouraging to hear that among our biotech customers, the interest level and funnels for those 2 portions of our portfolio have picked up here in the last several months.
And Justin, to your second question — oh, go ahead.
No. Please continue, Kim.
Yeah. Your other question concerned biotech trends, correct? So yes, during the past 12 months, the way funding is allocated has moved. And 12 months prior, it was obvious that 75% of the total funding was directed toward late-stage efforts, clinical development, Phase I, II, III, and now that figure stands at 82%. And the opposite pattern occurred for early-stage discovery, which previously accounted for 25% of budgets and at present represents 18% of the total funding. So early discovery took a decline. And that is precisely the issue we encountered with our core portfolio, particularly the assays Jim referenced; and in my view, that is not inherently a shift in competitive trends; it is simply a shift in where the money is directed.
I realize you already addressed this somewhat, but I'd like to pose one more — just a point of clarification regarding the guidance. You mentioned flat organic for fiscal Q4, which seems to suggest low single-digit growth underneath, once you set aside the GMP headwinds. Yet it appears there are fewer one-off items in that fiscal fourth quarter. The GMP reagent drag is quite minor, only 150 basis points. The OEM reagent timing pressures are behind you. On an organic basis, you had the simplest year-over-year comparison. Beyond biotech's performance, I mean, is anything else deteriorating?
Let me give a quick overview, and then Jim can go deeper. No, I'll start by looking at our end markets. Pharma has been growing at double digits, and funding there has held steady, perhaps even inching up. So we believe our entitlement remains double digits. Biotech, we've gone through in detail here. Academic, we're seeing a modest uptick, and we're thrilled to be back in positive territory for the first time; the market is still fragile; it definitely won't be a V-shaped recovery, in my view. But stabilizing and improving is a reasonable assumption there. And China, we've already covered — 4x in positive territory with ongoing momentum. So from that angle, I'm fairly at ease, and the one area we've been highlighting and feel might drag is still biotech. From a portfolio standpoint, our core has performed well, aside from those areas we've covered. And if you look at our verticals, I couldn't feel better. Cell therapy, we know about the 2 customers, but excluding them, underlying growth was 50%. We're seeing 17%, 12 trailing months. And that appears stable. We'd want that to be 20% minimum. So it's moving in that direction. Spatial, as you're aware, returned to mid-double digits with reagents getting better and the COMET instrument at 65% growth. Proteomic analysis, at present, sits at mid-single digits, and we do know it belongs in double digits, deep in double digits; so there, we believe the biotech pickup would be the catalyst to bring it back into the zone where it belongs, in mid-double digits; and then diagnostics, it was negative for the quarter, particularly the diagnostics — molecular diagnostics products. And that was plainly a timing matter. So there, I do see some favorable backdrop too, that it can return to a normal growth rate. So that's the quick overview on the product lines. So all in all, comfortable with, of course, being cautious for your next quarter, but with a strong path toward normalization.
Understood. And perhaps regarding the GMP reagent business, and also spatial on the Lunaphore side, the growth rates are quite remarkable — nearly 50% for GMP reagents, and beyond 60% for Lunaphore. I mean, how long do you believe these growth levels can be maintained moving forward? I mean, are they up against simple year-over-year comparisons?
Yeah. So — if you remove those 2 customers, we definitely examine the pipeline beneath that; we have more than 700 customers. Customer count is up by a mid-single-digit amount. So that isn't what's driving it. But what clearly propels it is customers moving further into their projects and spending additional money. We have 85 programs, identical to the prior quarter in clinical. That said, 18 sit in Phase II, whereas previously there were 15, and the same 6 customers remain in Phase III. So customers are achieving progress, and that fuels the growth. When you examine cell therapy trials around the world, those are rising considerably too. A mix shift has occurred, moving from gene therapy toward cell therapy, and we gain from that as well. So we do think that 20% growth as a floor for a 12-month trailing period would be the appropriate benchmark. And naturally, we can always examine our Wilson Wolf figures. We mentioned mid-single-digit growth during the most recent quarter, and that came on top of a comparable of 25% growth the year before. But the quantity of grants we are drafting there is remarkable. We're pleased that there are roughly 50% attachment rates involving Bio-Techne's cytokines and proteins; so on the whole, we feel at ease with the market's underlying activity levels, the pipeline's progress, and the number of customers we are adding into the funnel.
Perhaps only one from my side, and it builds on what was asked most recently regarding GMP proteins along with cell therapies. Could you possibly lay out what portion of that — what portion of the expansion you're observing originates from new program wins, as opposed to growth among customers you already have? That would be really helpful.
Sure, I briefly mentioned this already. I appreciate the question. The total count of our customers went up 3%. During the past two quarters or so, a rotation occurred. Certain customers moved out, having begun 2, 3 years back with an arrangement that ultimately proved possibly not a successful approach in cell therapy. Yet others arrived, and everything hinges on whether you can scale up. Can you make it cost effective, and we are definitely assisting our customers in doing that through the Wilson Wolf G-Rex along with our cytokines proteins and the ProPak form factor that we introduced a quarter or 2 ago; so on the whole, we find that 3% rise in customers, churn included, to be encouraging. Clinical studies are growing in number, and the pipeline shows advancement from — by the customers from clinicals 1 into 2 and 3. Thus we observe favorable movement across all 3 of those dimensions.
I appreciate all of you being on the line today. I'd like to acknowledge the team at Bio-Techne for staying dedicated and delivering results throughout a lengthy stretch of difficulties specific to the market and to particular customers; we take encouragement from clearer signs on biotech funding, a leveling off in U.S. academia, ongoing involvement by our major pharma clients, and steady forward motion in China along with the wider APAC area. As we pass through the 50th year of Bio-Techne, our portfolio is more closely matched to where science and medicine are heading than it has ever been. By pairing top-tier reagents with analytical platforms and enabling technologies, we underpin essential workflows spanning everything from initial discovery to translational research and manufacturing. Ongoing spending in cell therapy, proteomic analysis, spatial biology, and precision diagnostics leaves us well positioned to serve our customers and seize appealing opportunities for growth over the long term. Thanks once more for your interest in Bio-Techne, and we're eager to bring you an update on how we're doing next quarter.
Thanks. That wraps up the meeting for today. We’re grateful for the time you spent with us and for taking part. You’re welcome to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bio-Techne Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Bio-Techne Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.